Skye Bioscience, Inc. — Form SCHEDULE 13D/A
Filed August 18, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
5AM Partners VII, LLC filed an amended Schedule 13D/A regarding Skye Bioscience, Inc. on August 18, 2026. The filing document excerpt does not contain specific details on share count, ownership percentage, transaction amounts, or the nature of the amendment. Without access to the full filing content, concrete changes cannot be stated.
Why this rating
Schedule 13D/A amendments are routine disclosure updates for significant shareholders. Lack of concrete data in excerpt prevents full assessment; routine filing type suggests low materiality without confirmed major ownership shift.
See more from August 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.